日本单中心107例原发性甲状腺黏膜相关淋巴组织淋巴瘤的长期结局
日本伊藤医院回顾性分析107例IE或IIE期甲状腺MALT淋巴瘤患者,初始治疗包括单纯放疗58例、联合模式治疗48例、单纯化疗1例。5年总生存率94%、无事件生存率92%,10年分别为91%和84%;106例中71例(67%)治疗后出现甲状腺功能减退。结论认为局限期甲状腺MALT淋巴瘤长期结局良好。
要点
- 107例局限期甲状腺MALT淋巴瘤患者中,单纯放疗58例、联合模式治疗48例、单纯化疗1例。
- 5年总生存率94%(95%CI 87%–97%),10年91%(95%CI 83%–95%)。
- 106例可评估不良事件者中71例(67%)治疗后发生甲状腺功能减退。
核心结论
- 局限期甲状腺MALT淋巴瘤的长期结局良好,所有初始治疗模式均取得良好效果。
研究设计与样本
- 日本伊藤医院回顾性分析107例诊断为局限期(IE或IIE期)甲状腺MALT淋巴瘤患者的病历资料,中位年龄67岁,男性20例、女性87例。
主要发现
- 初始治疗为单纯放疗58例、联合模式治疗48例、单纯化疗1例;全部107例均对治疗有反应,其中6例复发,仅1例死于淋巴瘤。
- 5年总生存率为94%(95%CI 87%–97%),5年无事件生存率为92%(95%CI 85%–95%)。
- 10年总生存率为91%(95%CI 83%–95%),10年无事件生存率为84%(95%CI 74%–90%)。
- 106例有不良事件信息的患者中,71例(67%)在初始甲状腺淋巴瘤治疗后发生甲状腺功能减退。
- 联合模式治疗组出现化疗相关额外不良反应,包括中性粒细胞减少、神经病变、便秘和肺炎;联合模式治疗与放疗的5年总生存率分别为93%(95%CI 81%–98%)和94%(95%CI 84%–98%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid mucosa-associated lymphoid tissue (MALT) lymphoma is a type of extranodal lymphoma with a favorable prognosis. OBJECTIVE: To provide information on long-term outcomes that would facilitate establishment of the optimal management strategy for thyroid lymphoma. DESIGN, SETTING, AND PARTICIPANTS: Medical records of 107 patients (median age 67 years, 20 males, 87 females) who were diagnosed with localized thyroid MALT lymphoma stage IE or IIE at Ito Hospital were retrospectively reviewed. MAIN OUTCOME MEASURE: Overall and event-free survival (EFS). RESULTS: Initial treatments included radiation therapy (RT) alone (n = 58), combined modality therapy (CMT) (n = 48), or chemotherapy alone (n = 1). All 107 patients responded to the treatment, six of whom experienced relapse. Only one patient died of lymphoma. The 5-year overall survival (OS) and EFS rates were 94% [95% confidence interval (CI), 87% to 97%] and 92% (95% CI, 85% to 95%), respectively, and the 10-year OS and EFS rates were 91% (95% CI, 83% to 95%) and 84% (95% CI, 74% to 90%), respectively. Of the 106 patients with information available on adverse events, 71 patients (67%) developed hypothyroidism after primary thyroid lymphoma treatment. The CMT group showed additional chemotherapy-induced adverse reactions in the form of neutropenia, neuropathy, constipation, and pneumonia. The 5-year OS rates of patients treated with CMT and RT were 93% (95% CI, 81% to 98%) and 94% (95% CI, 84% to 98%), respectively. CONCLUSIONS: Long-term outcomes of localized thyroid MALT lymphoma are favorable with all initial treatment modalities.
引用
- Watanabe N, Narimatsu H, Noh JY, et al. Long-Term Outcomes of 107 Cases of Primary Thyroid Mucosa-Associated Lymphoid Tissue Lymphoma at a Single Medical Institution in Japan. J Clin Endocrinol Metab. 2018. PMID: 29165612. doi:10.1210/jc.2017-01478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。